Tissue Regenix Group PLC DermaPure gains Medicare coverage approval (7434G)
March 06 2015 - 2:09AM
UK Regulatory
TIDMTRX
RNS Number : 7434G
Tissue Regenix Group PLC
06 March 2015
Tissue Regenix Group plc
DermaPure receives Medicare coverage & reimbursement
YORK, 5 March 2015 - Tissue Regenix Group plc (AIM:TRX) ("Tissue
Regenix" or "the Group"), the regenerative medical devices company,
today announces its DermaPure(R) dermal allograft has received
notice of Local Coverage Determination (LCD) from the Medicare
Administrative Contractor (Novitas) that oversees Jurisdiction J-H
and Jurisdiction J-L, effective April 9, 2015. This represents a
key milestone in the post-acute or outpatient care setting for the
usage and reimbursement of DermaPure(R) for patient wound care.
After receiving a Q-code in January from the Center for Medicare
and Medicaid Services ("CMS"), the US Federal Government funded
health programme, LCD approval from the various jurisdictions is
the final step needed that enables the outpatient medical facility
to obtain reimbursement for the product for qualified patients.
The J-H jurisdiction spans the states of Colorado, New Mexico,
Oklahoma, Texas, Louisiana, Mississippi and Arkansas and the J-L
jurisdiction spans Washington DC, Delaware, Maryland, New Jersey
and Pennsylvania with total health care coverage for the two
jurisdictions of 8.9 million Medicare beneficiaries. This decision
will allow greater access to DermaPure(R) for clinicians and
provide an advanced treatment option for patients suffering from
chronic and acute wounds meeting medical necessity criteria.
Antony Odell, CEO of Tissue Regenix commented:
"DermaPure(R) has achieved outstanding clinical results in
numerous acute care institutions following its introduction in June
of last year. We are delighted with the opportunity to expand our
reach to help patients in the post-acute environment, including
wound care centers and ambulatory surgical centers. These
facilities represent a significant usage of skin substitutes for
wound care treatment."
Tissue Regenix will continue actively engaging with the other
LCD jurisdiction contractors to further the benefits of DermaPure
to healthcare providers and patients in other US geographies.
ENDS
For Further Information
Tissue Regenix Group Plc: +44 19 0443 5176
Antony Odell
Ian Jefferson
Jefferies International Ltd: +44 20 7029 8000
Simon Hardy
Harry Nicholas
Tulchan Communications: +44 207 353 4200
Tom Buchanan
Victoria Huxster
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. The company's patented decellularisation
('dCELL(R)') technology removes DNA and other cellular material
from animal and human tissue leaving an acellular tissue scaffold
which is not rejected by the patient's body which can then be used
to repair diseased or worn out body parts. The potential
applications of this process are diverse and address many critical
clinical needs such as vascular disease, heart valve replacement
and knee repair.
Tissue Regenix was formed in 2006 when it was spun-out from the
University of Leeds. The company commercialises academic research
conducted by our partners around the World.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States- 'Tissue Regenix Wound Care Inc.', as
part of its commercialisation strategy for its dCELL(R) technology
platform.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCPKADKOBKKANK
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Sep 2023 to Sep 2024